Sympathetic and Parasympathetic Divisions

The autonomic nervous system controls smooth muscle, cardiac muscle, and glands via a universal architecture: a preganglionic neuron with its cell body in the central nervous system projects to an autonomic ganglion, where it synapses on a postganglionic neuron whose axon reaches the target organ. What distinguishes the sympathetic from the parasympathetic division is where along this chain the cell bodies and ganglia are located, and which neurotransmitter-receptor pair operates at the final, organ-facing synapse. The sympathetic division is called "thoracolumbar" because its preganglionic neurons originate exclusively from the intermediolateral cell column of spinal segments T1 through L2 (roughly). These short preganglionic axons synapse in ganglia close to the spinal cord — the paravertebral sympathetic chain (paravertebral ganglia) running alongside the vertebral column, or in prevertebral ganglia (celiac, superior and inferior mesenteric) further out but still well short of the target organ. From there, long postganglionic axons travel the remaining distance to the heart, blood vessels, sweat glands, and viscera, releasing norepinephrine onto adrenergic receptors. One exception refines the picture: the adrenal medulla is itself a modified sympathetic ganglion — its chromaffin cells are directly innervated by preganglionic cholinergic fibers and act as a postganglionic "neuron" that secretes epinephrine (and some norepinephrine) as a hormone into the bloodstream rather than as a synaptic transmitter. The parasympathetic division is called "craniosacral" because its preganglionic neurons arise from four cranial nerve nuclei — oculomotor (CN III), facial (CN VII), glossopharyngeal (CN IX), and vagus (CN X) — and from sacral spinal segments S2–S4. These preganglionic axons are long, traveling almost all the way to the target organ before synapsing in small terminal ganglia embedded within or immediately adjacent to the organ wall itself. Postganglionic axons are correspondingly very short, releasing acetylcholine onto muscarinic receptors on the target cells. The vagus nerve alone carries roughly 75% of all parasympathetic outflow and innervates the heart, lungs, and most of the gastrointestinal tract down to the splenic flexure; the sacral outflow handles the distal colon, bladder, and reproductive organs.

Step 1 — Central command. Autonomic output is coordinated by the hypothalamus, brainstem nuclei (nucleus tractus solitarius, rostral ventrolateral medulla for sympathetic tone; dorsal motor nucleus of the vagus and nucleus ambiguus for parasympathetic tone), and descending spinal pathways. These centers integrate baroreceptor, chemoreceptor, and limbic (emotional/stress) input and set the preganglionic firing rate.

Step 2 — Preganglionic transmission (shared logic). In both divisions, the preganglionic neuron releases acetylcholine (ACh) onto nicotinic acetylcholine receptors (nAChRs) on the postganglionic neuron. Nicotinic receptors are ligand-gated cation channels; ACh binding opens the channel, Na⁺ influx depolarizes the postganglionic cell, and if threshold is reached, an action potential propagates down the postganglionic axon. This synapse is pharmacologically identical in both divisions — a fact exploited by ganglionic blockers (e.g., hexamethonium), which shut down both sympathetic and parasympathetic outflow simultaneously.

Step 3 — Postganglionic transmission (the divergence). Here the two divisions differ decisively.

• Sympathetic postganglionic neurons release norepinephrine (NE), which binds adrenergic receptors: α1 (Gq-coupled, vasoconstriction, mydriasis), α2 (Gi-coupled, presynaptic autoinhibition), β1 (Gs-coupled, increased heart rate and contractility), and β2 (Gs-coupled, bronchodilation, vasodilation in skeletal muscle, relaxation of GI smooth muscle). Sympathetic postganglionic fibers to sweat glands are the notable exception — they release ACh acting on muscarinic receptors, a developmental oddity in an otherwise adrenergic division.
• Parasympathetic postganglionic neurons release acetylcholine, which binds muscarinic acetylcholine receptors (mAChRs), G-protein-coupled receptors of five subtypes (M1–M5). M2 receptors in the heart (Gi-coupled) slow heart rate; M3 receptors in smooth muscle and glands (Gq-coupled) drive contraction and secretion.

Step 4 — Receptor identity determines organ response, not the neurotransmitter alone. Because different organs express different receptor subtypes, the "meaning" of a given transmitter is entirely context-dependent. Norepinephrine constricts most blood vessels (α1) but dilates skeletal-muscle vasculature and bronchioles when acting on β2 (though this is more classically a response to circulating epinephrine). Acetylcholine slows the heart via M2 but increases GI motility via M3 — opposite-seeming effects that make sense once receptor coupling (Gi vs. Gq) is specified.

Step 5 — Organ-level integration: antagonism, cooperation, or sole innervation. At the heart, sinoatrial node pacemaker cells receive continuous antagonistic input: vagal ACh (M2, via Gi) hyperpolarizes and slows the pacemaker, while sympathetic NE (β1, via Gs) speeds it up — resting heart rate reflects a tug-of-war won mostly by vagal tone (hence "vagal brake"). At the eye, the iris shows reciprocal innervation: sympathetic activation dilates the pupil (radial muscle, α1) while parasympathetic activation constricts it (sphincter muscle, M3). At the salivary glands, both divisions increase secretion but change its character — parasympathetic input produces copious watery saliva, sympathetic input produces small volumes of thick, protein-rich saliva — a case of cooperative rather than antagonistic control. Cutaneous blood vessels and sweat glands receive sympathetic innervation only; there is no parasympathetic supply to skin vasculature, so "antagonism" is a common organizing principle but not a universal law of autonomic anatomy.

The claim that sympathetic and parasympathetic nerves act via different chemical messengers, rather than by direct electrical action or by a single universal transmitter, was established by two convergent lines of experimentation in the early twentieth century.

Otto Loewi's "Vagusstoff" experiment (1921). Loewi isolated two frog hearts, keeping each perfused in its own saline-filled chamber but connecting the fluid pathways so that fluid leaving the first heart could be transferred to bathe the second. He electrically stimulated the vagus nerve innervating the first heart, causing it to slow, exactly as expected. He then transferred the perfusate from that first heart's chamber onto the second, unstimulated heart — and the second heart also slowed down, even though its own vagus had never been touched. This proved that vagal stimulation released a diffusible chemical substance (which Loewi called Vagusstoff, later identified as acetylcholine by Loewi and Henry Dale) into the bathing fluid, and that this substance alone was sufficient to reproduce the inhibitory effect. Loewi reportedly conceived the entire experimental design in a dream and performed it the following night — a story he himself recounted, though the underlying experiment and result are rigorously documented and repeatable. Loewi and Dale shared the 1936 Nobel Prize in Physiology or Medicine for establishing chemical neurotransmission.

Walter Cannon and "Sympathin" (1920s–1930s). Walter Cannon, who coined the term "fight-or-flight," performed parallel experiments on sympathetic nerves innervating the heart and other organs. Stimulating sympathetic nerves accelerated the heart and could be shown, by analogous transfer experiments, to release a diffusible excitatory substance he named "Sympathin." Cannon and his collaborator Arturo Rosenblueth further showed that this substance came in at least two functionally distinct forms — an excitatory Sympathin E and an inhibitory Sympathin I — anticipating the later pharmacological discovery that a single molecule, norepinephrine, produces opposite effects depending on which adrenergic receptor subtype it engages. The chemical identity of Sympathin as norepinephrine was confirmed later by Ulf von Euler (1946), who directly measured norepinephrine in sympathetic nerve extracts using bioassay and later chromatographic methods, work for which he shared the 1970 Nobel Prize.

What these experiments proved, together: (1) Neurons communicate with target organs by releasing diffusible chemical substances, not by direct electrical continuity — settling the "soup versus sparks" debate in favor of chemical transmission at the neuroeffector junction; (2) the sympathetic and parasympathetic divisions use different transmitters (norepinephrine vs. acetylcholine), providing the molecular basis for why they can be pharmacologically manipulated independently — for instance, atropine (a muscarinic antagonist) blocks parasympathetic effects on the heart without touching sympathetic tone, while propranolol (a β-blocker) does the reverse; (3) the same transmitter can produce opposite physiological outcomes depending on receptor coupling, a principle later mapped in molecular detail by Robert Lefkowitz and Brian Kobilka's work characterizing G-protein-coupled receptors (Nobel Prize, 2012), which explained mechanistically why α1 and β2 adrenergic receptors, both activated by norepinephrine or epinephrine, drive opposite vascular responses in different tissues.

Example 1 — Pharmacological dissection of a mixed autonomic drug. A patient is given atropine (a competitive muscarinic antagonist) intravenously. Before the drug, resting heart rate is 70 bpm. After atropine, heart rate rises to 100 bpm and then plateaus even at higher doses. A student is asked: what does this reveal about baseline autonomic balance at the heart, and why doesn't heart rate rise further? Reasoning: The heart's intrinsic pacemaker rate — the rate the SA node would fire with no autonomic input at all — is approximately 100–110 bpm, as demonstrated by transplanted (denervated) hearts, which typically beat at 100–110 bpm with no fluctuation from breathing or stress. Resting rate in an intact person (≈70 bpm) is lower than this intrinsic rate, which tells us that at rest, tonic vagal (parasympathetic) inhibition dominates over sympathetic drive — the "vagal brake." Atropine blocks M2 receptors, removing vagal inhibition entirely, so heart rate rises toward the intrinsic pacemaker rate (~100 bpm). It plateaus there rather than climbing further because atropine has not added any sympathetic stimulation — it has only removed a parasympathetic brake. To push heart rate further, you would need a β1 agonist (e.g., isoproterenol) to actively drive the SA node above its intrinsic rate. This experiment (routinely performed in autonomic pharmacology labs and in cardiac transplant physiology) demonstrates that resting heart rate is not a "sympathetic baseline" but predominantly a parasympathetically suppressed intrinsic rate.

Example 2 — Predicting a receptor-selective drug's effect from anatomy and receptor logic. A new drug is a selective α1-adrenergic receptor antagonist (structurally similar to prazosin, used clinically for hypertension and benign prostatic hyperplasia). Predict its effects on (a) blood pressure, (b) pupil diameter, and (c) heart rate, and explain each using the mechanism above. Reasoning:

• (a) Blood pressure: Most systemic arterioles are under tonic sympathetic vasoconstrictor tone via α1 receptors (Gq → IP3/Ca²⁺ → smooth muscle contraction). Blocking α1 removes this constrictor tone, so vessels dilate and total peripheral resistance falls; since blood pressure = cardiac output × total peripheral resistance, BP decreases. This is exactly why α1-blockers are used as antihypertensives.
• (b) Pupil diameter: The iris's radial (dilator) muscle is controlled by sympathetic α1 receptors; blocking them removes dilation drive, so the unopposed parasympathetic sphincter (M3) input dominates and the pupil constricts slightly (miosis), though this effect is modest since ambient light level and parasympathetic tone are the primary drivers of pupil size.
• (c) Heart rate: The SA node's rate control is dominated by β1 (sympathetic) and M2 (parasympathetic) receptors, not α1. Since the drug is α1-selective, direct cardiac rate effects should be minimal — but because BP has dropped (from a), the baroreceptor reflex will sense reduced arterial pressure and reflexively increase sympathetic outflow to the heart via β1 receptors, producing a modest compensatory tachycardia. This is a clinically documented side effect of α1-blockers and illustrates that autonomic effects must be traced through reflex loops, not just direct receptor pharmacology.

Otto Loewi (1873–1961) trained as a physician in Germany and Austria and, before his famous 1921 experiment, had already spent nearly two decades investigating cardiac physiology and drug action on isolated organs. He was a close friend and correspondent of Henry Dale, with whom he would later share the Nobel Prize — the two had met as young researchers in England and maintained a lifelong scientific partnership that bridged Loewi's physiological demonstrations with Dale's chemical identification of acetylcholine. Loewi's career was brutally interrupted: as an Austrian Jew, he was arrested by the Gestapo after the 1938 Anschluss, briefly imprisoned, and forced to surrender his Nobel Prize money to secure his and his family's emigration. He spent the rest of his career at New York University, continuing to study synaptic transmission and drug pharmacology until his death.

The sympathetic/parasympathetic distinction underlies enormous swaths of clinical pharmacology. Beta-blockers (propranolol, metoprolol) treat hypertension, angina, and arrhythmias by blocking sympathetic β1 receptors in the heart. Alpha-1 blockers (prazosin, tamsulosin) treat hypertension and benign prostatic hyperplasia by relaxing sympathetically-toned smooth muscle. Anticholinergic drugs (atropine, ipratropium) counter excessive parasympathetic tone in bradycardia, bronchospasm (asthma/COPD), and are used to dry secretions before surgery, while cholinesterase inhibitors (pyridostigmine, donepezil) boost cholinergic — including parasympathetic — signaling in myasthenia gravis and Alzheimer's disease respectively. Epinephrine auto-injectors (EpiPens) exploit β2 (bronchodilation) and α1 (vasoconstriction) adrenergic action to reverse anaphylactic shock within minutes. Understanding vagal tone underlies biofeedback and heart-rate-variability-based clinical monitoring, since reduced HRV (reflecting diminished parasympathetic modulation) is a validated risk marker for cardiovascular mortality. In diabetes and Parkinson's disease, autonomic neuropathy disrupts this balance, producing orthostatic hypotension and gastroparesis that clinicians diagnose using tilt-table and gastric-emptying tests grounded directly in this two-division framework. The same principles extend into the gut, where local reflex circuits interact with sympathetic and parasympathetic input — the subject taken up next in the The Enteric Nervous System.

Ask the tutor: How do baroreceptor reflexes use both divisions together to keep blood pressure stable during a sudden drop in blood volume?